Acousia
5 known investors
Acousia develops small molecule drug candidates with a dual mode of action to enhance and preserve natural hearing in patients with sensorineural hearing loss (SNHL), targeting indications such as age-related hearing loss, cisplatin-induced and aminoglycoside ototoxicity, and cochlear implant surgery. Its lead candidate ACOU085 entered a first-in-human clinical study in age-related hearing loss in 2022.
BiotechDigital HealthMedical Devices
Investors · 5
In the news
Frequently asked questions
- What does Acousia do?
- Acousia develops small molecule drug candidates with a dual mode of action to enhance and preserve natural hearing in patients with sensorineural hearing loss (SNHL), targeting indications such as age-related hearing loss, cisplatin-induced and aminoglycoside ototoxicity, and cochlear implant surgery. Its lead candidate ACOU085 entered a first-in-human clinical study in age-related hearing loss in 2022.
- Who are Acousia's investors?
- Acousia's investors include Creathor Ventures, LBBW Venture Capital GmbH, Boehringer Ingelheim Venture Fund, Esperante Ventures, KfW.